ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
2
views
0
references
Top references
cited by
20
Cite as...
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,590
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Durability of brain metastasis response and overall survival in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab.
Author(s):
Sarah B. Goldberg
1
,
Scott N. Gettinger
1
,
Amit Mahajan
1
,
Roy S. Herbst
1
,
Anne C. Chiang
1
,
Rogerio Lilenbaum
1
,
Lucia Jilaveanu
1
,
Elin Rowen
1
,
Heather Gerrish
1
,
Annette Komlo
1
,
Wei Wei
2
,
Veronica Chiang
1
,
Harriet M. Kluger
1
Publication date
Created:
May 20 2018
Publication date
(Print):
May 20 2018
Journal:
Journal of Clinical Oncology
Publisher:
American Society of Clinical Oncology (ASCO)
Read this article at
ScienceOpen
Publisher
PubMed
Review
Review article
Invite someone to review
Bookmark
Cite as...
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Inflamed lung in vitro co-culture models
Author and article information
Journal
Title:
Journal of Clinical Oncology
Abbreviated Title:
JCO
Publisher:
American Society of Clinical Oncology (ASCO)
ISSN (Print):
0732-183X
ISSN (Electronic):
1527-7755
Publication date Created:
May 20 2018
Publication date (Print):
May 20 2018
Volume
: 36
Issue
: 15_suppl
Page
: 2009
Affiliations
[
1
]
Yale School of Medicine, New Haven, CT;
[
2
]
Yale School of Public Health, New Haven, CT;
Article
DOI:
10.1200/JCO.2018.36.15_suppl.2009
PubMed ID:
29787359
SO-VID:
34551e53-1b3a-4f6a-b6df-c93a61273034
Copyright ©
© 2018
History
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
1,590
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)
Authors:
Douglas G McNeel
,
Jens Eickhoff
,
Ellen Wargowski
…
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer
Authors:
N.Y.L. Ngoi
,
V Heong
,
X.W. Lee
…
WHO, RECIST, and immune-related response criteria: is it time to revisit pembrolizumab results?
Authors:
Felipe Ades
,
Nise Yamaguchi
See all similar
Cited by
19
Immunotherapy of brain metastases: breaking a “dogma”
Authors:
Anna Maria Di Giacomo
,
Monica Valente
,
Alfonso Cerase
…
PD-1/PD-L1 Blockers in NSCLC Brain Metastases: Challenging Paradigms and Clinical Practice
Authors:
Iñaki Eguren-Santamaría
,
Miguel F. Sanmamed
,
Sarah B Goldberg
…
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-small Cell Lung Cancer
Authors:
Jose M. Pacheco
,
D. Ross Camidge
,
Robert Doebele
…
See all cited by